openPR Logo
Press release

Familial Lipoprotein Lipase Deficiency Market Growth Trends, Regional Analysis, Type, Application, Restraints, and Key Players Forecast to 2031 - Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.

10-09-2024 08:53 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Familial Lipoprotein Lipase Deficiency Market || 2024-2031

Familial Lipoprotein Lipase Deficiency Market || 2024-2031

DataM Intelligence has released a new research report on the Familial Lipoprotein Lipase Deficiency market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits, gross margins, and strategic decisions in the global market. The report is enriched with tables, charts, and infographics for a clear presentation of the findings.

The Familial Lipoprotein Lipase Deficiency Market is valued at at a high CAGR during the forecast period (2024-2031).

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/familial-lipoprotein-lipase-deficiency-market

Familial lipoprotein lipase deficiency (LPLD) is a rare genetic disorder caused by mutations in the LPL gene, which is crucial for producing the lipoprotein lipase enzyme. This enzyme plays a key role in metabolizing triglycerides from lipoproteins into free fatty acids, which are used by the body for energy. Individuals with LPLD experience severe hypertriglyceridemia, leading to complications such as pancreatitis, abdominal pain, and an increased risk of cardiovascular disease. The condition is inherited in an autosomal recessive pattern, meaning both copies of the gene must be mutated for symptoms to manifest. Treatment options are limited and may include dietary modifications, fibrate medications, and in some cases, enzyme replacement therapy. Early diagnosis and management are vital to prevent serious health issues associated with the disorder.

List of the Key Players in the Familial Lipoprotein Lipase Deficiency Market:

Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Aetna Inc., Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., MANUS AKTTEVA BIOPHARMA LLP, Silverline Chemicals, Sainor, GSK plc, and PTC Therapeutics among others.

Key Developments:

In December 2023, Ultragenyx Pharmaceutical Inc. announced that the European Commission (EC) has expanded the approval of Evkeeza for use as an adjunct to diet and other lipid-lowering therapies in treating children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). This milestone makes Evkeeza the first treatment specifically indicated for children as young as 5 years old that inhibits angiopoietin-like 3 (ANGPTL3), a key protein involved in lipid metabolism. The approval highlights Evkeeza's role in managing dangerously high levels of low-density lipoprotein cholesterol (LDL-C) associated with HoFH, a genetic condition that leads to extremely elevated cholesterol levels. The expanded indication underscores Ultragenyx's commitment to addressing the needs of pediatric patients with challenging lipid disorders.

Research Process:

Both primary and secondary data sources have been used in the global Familial Lipoprotein Lipase Deficiency Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Familial Lipoprotein Lipase Deficiency Market:

By Treatment Type: Olezarsen, Evinacumab ,Orlistat ,Alipogene Tiparvovec.

By Age Group: 1-10 Years , 13-60 Years.

By Gender: Male, Female.

By End-User: Hospitals & Specialty Clinics , Ambulatory Surgical Centers, Others.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/familial-lipoprotein-lipase-deficiency-market

Regional Analysis:

➣ North America (US, Canada, Mexico)

➣ Europe (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)

➣ Asia-Pacific (China, India, Japan, Australia, Rest of Asia Pacific)

➣ South America (Brazil, Argentina, Rest of South America)

➣ Middle East and Africa

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Familial Lipoprotein Lipase Deficiency market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Familial Lipoprotein Lipase Deficiency Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Familial Lipoprotein Lipase Deficiency market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Familial Lipoprotein Lipase Deficiency Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/familial-lipoprotein-lipase-deficiency-market

The Research Report Offers Answers To The Following Questions:

☛ What is the expected growth rate of the global market for the forecast period?

☛ What are the key driving factors that are responsible to shape the fate of the Familial Lipoprotein Lipase Deficiency market during the forecast period?

☛ What will be the overall size of the market during the analysis period?

☛ What are the prominent market trends which influence the development of the Familial Lipoprotein Lipase Deficiency market across various regions?

☛ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☛ What are the challenges and threats that are likely to act as a barrier to the growth of the Familial Lipoprotein Lipase Deficiency market?

☛ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Familial Lipoprotein Lipase Deficiency Market Growth Trends, Regional Analysis, Type, Application, Restraints, and Key Players Forecast to 2031 - Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. here

News-ID: 3683840 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Natural Astaxanthin Market to Reach USD 1.5 Billion by 2031, Growing at a CAGR of 7.7% | Rising Demand in Nutraceuticals and Aquaculture
United States Natural Astaxanthin Market to Reach USD 1.5 Billion by 2031, Growi …
Global Natural Astaxanthin Market reached US$ 0.84 billion in 2023 and is expected to reach US$ 1.5 billion by 2031, growing with a CAGR of 7.7% during the forecast period 2024-2031. The Natural Astaxanthin Market focuses on the use of astaxanthin, a powerful antioxidant derived from microalgae, in industries like food and beverages, pharmaceuticals, cosmetics, and nutraceuticals. Known for its health benefits, such as reducing inflammation and supporting skin health, the
Remote Browser Isolation Market reached US$ 0.59 billion in 2024 and is expected to reach US$ 5.35 billion by 2032 | Broadcom, Cisco, Cloudflare, ConnX
Remote Browser Isolation Market reached US$ 0.59 billion in 2024 and is expected …
Remote Browser Isolation Market reached US$ 0.59 billion in 2024 and is expected to reach US$ 5.35 billion by 2032, growing with a CAGR of 31.75% during the forecast period 2025-2032. Remote Browser Isolation (RBI) is a cybersecurity technology that separates a user's web browsing activity from their local network and endpoints by running the browser sessions on remote servers. This approach prevents malware, ransomware, and phishing attacks from reaching the
United States Liquid Chromatography Mass Spectrometry Market to Reach USD 19.10 Billion by 2032, Growing at a CAGR of 13.82% | Expanding Applications in Pharma, Biotech, and Food Safety
United States Liquid Chromatography Mass Spectrometry Market to Reach USD 19.10 …
The Liquid Chromatography Mass Spectrometry Market size reached US$ 6.78 billion in 2024 and is expected to reach US$ 19.10 billion by 2032, growing with a CAGR of 13.82% during the forecast period 2025-2032. LC-MS combines liquid chromatography and mass spectrometry for highly sensitive chemical, proteomic, and pharmaceutical analysis. Growth is driven by drug discovery, clinical diagnostics, and environmental testing. Applications include metabolomics, food safety, and biomarker identification. Research labs, pharmaceutical
United States Algae-Based Food Products Market Outlook 2024-2031: Rising Demand for Natural Proteins and Functional Nutrition | Top Companies are Cargill, Incorporated, AlgoSource E
United States Algae-Based Food Products Market Outlook 2024-2031: Rising Demand …
Global Algae-Based Food Products Market reached US$ 2.1 billion in 2023 and is expected to reach US$ 3.8 billion by 2031, growing with a CAGR of 7.69 % during the forecast period 2024-2031. The Algae-Based Food Products Market includes functional foods, beverages, and supplements made from spirulina, chlorella, and other algae. Growth is driven by health trends, vegan diets, and sustainability awareness. Products provide protein, omega-3s, antioxidants, and vitamins. Food manufacturers,

All 5 Releases


More Releases for Familial

Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. Download the sample report at: https://www.pharmaproff.com/request-sample/1025 A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke. Download the sample report @ https://www.pharmaproff.com/request-sample/1135 A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or